Analyst Price Forecast Suggests 395.71% Upside As of December 23, 2024, the average one-year price target for enGene Holdings is $28.90/share. The forecasts range from a low of $16.16 to a high of ...

On Monday, H.C. Wainwright began coverage on Engene Holdings Inc. (NASDAQ:ENGN) with a Buy rating and a price target of $25.00. The firm's analyst highlighted the potential of enGene's gene ...

H.C. Wainwright analyst Andres Maldonado initiated coverage of enGene (ENGN) with a Buy rating and $25 price target The firm says the The non-muscle invasive bladder cancer treatment landscape is ...

enGene Trading Down 2.2 % Shares of NASDAQ ENGN opened at $5.83 on Monday. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. enGene Holdings Inc ...

enGene Holdings Inc. (NASDAQ:ENGN), a $304 million market cap biotech firm whose shares have declined 35% year-to-date, has entered into a sales agreement with Jefferies LLC, enabling the company to ...

enGene Holdings Inc. (ENGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

Cette étape débute dans la célèbre localité de Derborence. En haut, vous devinez la langue du glacier des Diablerets. La Quille du Diable ou Tour Saint-Martin se dresse, solitaire, au bord de l’abîme.

enGene (ENGN) is in a strong clinical and financial position as we close the year,” said Ron Cooper, Chief Executive Officer of enGene. “With trial recruitment open across all cohorts ...

BOSTON & MONTREAL, December 19, 2024--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...